Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results from the PIANO registry.

Rishika ChughMillie D LongYue JiangKimberly N WeaverDawn B BeaulieuEllen J ScherlUma Mahadevan

Published in: The American journal of gastroenterology (2023)

This analysis of UST and VDZ exposure during pregnancy suggests no increase in complications compared to TNFs, immunomodulators and combination TNFs/immunomodulators. No signal was found for increased placental events with either therapy. Continuation of UST and VDZ throughout pregnancy is recommended.

Keyphrases

pregnancy outcomes
preterm birth
pregnant women
birth weight
gestational age
ulcerative colitis
risk factors
patients with inflammatory bowel disease
type diabetes
stem cells
physical activity
bone marrow
cell therapy
weight gain